Information Provided By:
Fly News Breaks for November 5, 2019
XNCR
Nov 5, 2019 | 20:47 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target on Xencor to $46 after its Q3 results and also to reflect his reduced estimated value for XmAb5871 and XmAb7195 programs. The analyst notes that the company does not plan to advance its obexelimab, or XmAb5871, program in either IgG4-Related Disease or lupus without a partner, adding that the same applies to XmAb7195 in asthma. The analyst still keeps his Overweight rating on the stock.
News For XNCR From the Last 2 Days
There are no results for your query XNCR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.